US Patent Issued to Medicenna Therapeutics on Aug. 11 for "Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)" (Canadian Inventor)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,702,710, issued on Aug. 11, was assigned to Medicenna Therapeutics Inc. (Toronto).

"Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)" was invented by Fahar Merchant (Vancouver, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods for treating a central nervous system (CNS) tumor in a subject, comprising administering to the subject MD-NA55 in combination with a vascular endothelial growth factor A (VEGF-A) inhibitor administered at a subtherapeutic level."

The patent was filed on Oct. 12, 2021, under Application No. 18/248,601.

*For further information, including images, charts and tables, please visit: http:/...